melatonin has been researched along with Mouth Neoplasms in 18 studies
Mouth Neoplasms: Tumors or cancer of the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has a powerful antioxidant and oncostatic effects that are expected to improve tumor hypoxia and clinical response." | 2.94 | Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial. ( Abdullah, M; Haryana, SM; Jusman, SW; Kartini, D; Maruli, H; Panigoro, SS; Purwanto, DJ; Rustamadji, P; Setiabudy, R; Siregar, BH; Sungkar, S; Suroyo, I; Sutandyo, N; Taher, A, 2020) |
| "Melatonin (MLT) is a molecule secreted by the pineal gland in cyclical periods." | 2.47 | Melatonin and cancer: current knowledge and its application to oral cavity tumours. ( Aneiros-Cachaza, J; Aneiros-Fernández, J; Arias-Santiago, S; Cutando, A, 2011) |
| "Oral squamous cell carcinomas are one of the most common cancers worldwide with aggressive behavior and poor prognosis." | 1.91 | Melatonin and erastin emerge synergistic anti-tumor effects on oral squamous cell carcinoma by inducing apoptosis, ferroptosis, and inhibiting autophagy through promoting ROS. ( Choi, WS; Li, X; Su, Y; Tao, Z; Wang, C; Wang, L; Zhu, W, 2023) |
| "Melatonin receptors can inhibit breast and prostate cancers; however, little is known regarding their effects on oral squamous cell carcinoma." | 1.72 | Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients. ( Hwang, DS; Jang, MA; Kim, GC; Kim, UK; Park, HK; Ryu, MH, 2022) |
| "Melatonin has been demonstrated to exhibit oncostatic effects." | 1.62 | Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway. ( Choi, WS; Su, Y; Wang, L, 2021) |
| "Lip, oral cavity, and pharyngeal cancers (LOCP) constitute a group of rare neoplasms with unfavorable prognosis." | 1.62 | Parameters of Oxidative Stress, Vitamin D, Osteopontin, and Melatonin in Patients with Lip, Oral Cavity, and Pharyngeal Cancer. ( Czuczejko, J; Maruszak, M; Małkowski, B; Nuszkiewicz, J; Pawłowska, M; Szewczyk-Golec, K; Woźniak, A, 2021) |
| "Melatonin treatment enhanced arecoline-induced ROS production, cytotoxicity, G2/M phase arrest, and cell apoptosis in OSCC cells." | 1.62 | Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma. ( Chiu, KC; Hsia, SM; Lan, WC; Shieh, TM; Shih, YH; Tsai, BH; Wang, TH; Wu, LJ, 2021) |
| "Globally, oral cancer is the most common type of head and neck cancers." | 1.48 | Melatonin Inhibits Reactive Oxygen Species-Driven Proliferation, Epithelial-Mesenchymal Transition, and Vasculogenic Mimicry in Oral Cancer. ( Chen, FM; Deng, MJ; Duan, WF; Li, L; Liu, R; Mo, YY; Nie, X; Wang, HL; Wen, XJ; Zou, CL, 2018) |
| "By assessing oral squamous cell carcinoma (OSCC) tissue arrays through immunohistochemistry, we examined whether aberrant LSD1 overexpression in OSCC is associated with poor prognosis." | 1.46 | Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models. ( Chen, YW; Hsieh, CC; Lin, CK; Lin, GJ; Ma, KH; Shieh, YS; Sytwu, HK; Tsao, CH; Yang, CY, 2017) |
| "Treatment with melatonin did not demonstrate inhibition of the expression of genes HIF-1α, VEGF and ROCK-1 in line SCC25, which has different molecular characteristics and greater degree of malignancy when compared to the line SCC9." | 1.40 | Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. ( Colombo, J; Goncalves, Ndo N; Jardim-Perassi, BV; Lopes, JR; Moschetta, MG; Rodrigues, RV; Zuccari, DA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 12 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Park, HK | 1 |
| Ryu, MH | 1 |
| Hwang, DS | 1 |
| Kim, GC | 1 |
| Jang, MA | 1 |
| Kim, UK | 1 |
| Shigeishi, H | 1 |
| Yokoyama, S | 1 |
| Murodumi, H | 1 |
| Sakuma, M | 1 |
| Fukada, S | 1 |
| Okuda, S | 1 |
| Yamakado, N | 1 |
| Ono, S | 1 |
| Takechi, M | 1 |
| Ohta, K | 1 |
| Wang, L | 3 |
| Su, Y | 3 |
| Choi, WS | 3 |
| Nuszkiewicz, J | 1 |
| Czuczejko, J | 1 |
| Maruszak, M | 1 |
| Pawłowska, M | 1 |
| Woźniak, A | 1 |
| Małkowski, B | 1 |
| Szewczyk-Golec, K | 1 |
| Wang, C | 2 |
| Tao, Z | 2 |
| Zhu, W | 2 |
| Li, X | 1 |
| Dholariya, S | 1 |
| Singh, RD | 1 |
| Patel, KA | 1 |
| Kartini, D | 1 |
| Taher, A | 1 |
| Panigoro, SS | 1 |
| Setiabudy, R | 1 |
| Jusman, SW | 1 |
| Haryana, SM | 1 |
| Abdullah, M | 1 |
| Rustamadji, P | 1 |
| Purwanto, DJ | 1 |
| Sutandyo, N | 1 |
| Suroyo, I | 1 |
| Siregar, BH | 1 |
| Maruli, H | 1 |
| Sungkar, S | 1 |
| Shih, YH | 1 |
| Chiu, KC | 1 |
| Wang, TH | 1 |
| Lan, WC | 1 |
| Tsai, BH | 1 |
| Wu, LJ | 1 |
| Hsia, SM | 1 |
| Shieh, TM | 1 |
| Madapusi Balaji, T | 1 |
| Varadarajan, S | 1 |
| Jagannathan, R | 1 |
| Raj, AT | 1 |
| Sridhar, LP | 1 |
| Patil, S | 1 |
| Salarić, I | 1 |
| Karmelić, I | 1 |
| Lovrić, J | 1 |
| Baždarić, K | 1 |
| Rožman, M | 1 |
| Čvrljević, I | 1 |
| Zajc, I | 1 |
| Brajdić, D | 1 |
| Macan, D | 1 |
| Su, SC | 2 |
| Yeh, CM | 2 |
| Lin, CW | 2 |
| Hsieh, YH | 1 |
| Chuang, CY | 1 |
| Tang, CH | 1 |
| Lee, YC | 1 |
| Yang, SF | 2 |
| Yang, CY | 1 |
| Lin, CK | 1 |
| Tsao, CH | 1 |
| Hsieh, CC | 1 |
| Lin, GJ | 1 |
| Ma, KH | 1 |
| Shieh, YS | 1 |
| Sytwu, HK | 1 |
| Chen, YW | 1 |
| Liu, R | 1 |
| Wang, HL | 1 |
| Deng, MJ | 1 |
| Wen, XJ | 1 |
| Mo, YY | 1 |
| Chen, FM | 1 |
| Zou, CL | 1 |
| Duan, WF | 1 |
| Li, L | 1 |
| Nie, X | 1 |
| Goncalves, Ndo N | 1 |
| Rodrigues, RV | 1 |
| Jardim-Perassi, BV | 1 |
| Moschetta, MG | 1 |
| Lopes, JR | 1 |
| Colombo, J | 1 |
| Zuccari, DA | 1 |
| Yang, JS | 1 |
| Yang, WE | 1 |
| Gómez-Moreno, G | 1 |
| Guardia, J | 1 |
| Ferrera, MJ | 1 |
| Cutando, A | 2 |
| Reiter, RJ | 1 |
| Aneiros-Fernández, J | 1 |
| Aneiros-Cachaza, J | 1 |
| Arias-Santiago, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC)[NCT04137627] | Phase 3 | 50 participants (Actual) | Interventional | 2017-07-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Expression of CD133 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 1.13 | 1.42 | 0.43 |
| Placebo | 1.07 | 1.88 | 0.55 |
Expression of CD44 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 0.0349 | 0.0115 | -0.0114 |
| Placebo | 0.0095 | 0.0187 | 0.0082 |
Expression of HIF-1⍺ is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 0.018 | 0.012 | -0.008 |
| Placebo | 0.0048 | 0.0087 | 0.0027 |
Expression of miR-210 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Mean) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 162.8 | 53.8 | -109.09 |
| Placebo | 175.2 | 53.5 | -103.71 |
3 reviews available for melatonin and Mouth Neoplasms
| Article | Year |
|---|---|
Melatonin: Emerging Player in the Management of Oral Cancer.
Topics: Antioxidants; Humans; Melatonin; Mouth Neoplasms | 2023 |
Melatonin in diseases of the oral cavity.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Candida albicans; Candidiasis, Oral; Dental Caries; | 2010 |
Melatonin and cancer: current knowledge and its application to oral cavity tumours.
Topics: Antioxidants; Carcinoma; Humans; Melatonin; Mouth Neoplasms; Receptors, Melatonin | 2011 |
1 trial available for melatonin and Mouth Neoplasms
| Article | Year |
|---|---|
Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; C | 2020 |
14 other studies available for melatonin and Mouth Neoplasms
| Article | Year |
|---|---|
Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastas | 2022 |
Melatonin enhances cisplatin-induced cell death through inhibition of DERL1 in mesenchymal-like CD44
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Gene Expressi | 2022 |
Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway.
Topics: Carcinoma, Squamous Cell; Cell Movement; Cell Survival; Fibroblast Growth Factors; Gene Expression R | 2021 |
Parameters of Oxidative Stress, Vitamin D, Osteopontin, and Melatonin in Patients with Lip, Oral Cavity, and Pharyngeal Cancer.
Topics: Aged; Biomarkers, Tumor; Case-Control Studies; Female; Humans; Lip Neoplasms; Male; Melatonin; Middl | 2021 |
Tumor-associated macrophages facilitate oral squamous cell carcinomas migration and invasion by MIF/NLRP3/IL-1β circuit: A crosstalk interrupted by melatonin.
Topics: Animals; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Intramolecular Oxidoreductases; | 2023 |
Melatonin and erastin emerge synergistic anti-tumor effects on oral squamous cell carcinoma by inducing apoptosis, ferroptosis, and inhibiting autophagy through promoting ROS.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Disease Models, Animal; Ferroptosis; Head a | 2023 |
Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma.
Topics: Areca; Arecoline; Carcinoma, Squamous Cell; DNA Damage; Humans; Melatonin; Mouth Neoplasms; Reactive | 2021 |
Hypothesizing the potential role of melatonin in inhibiting epithelial to mesenchymal transition in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; Melatonin; Mo | 2020 |
Salivary melatonin in oral squamous cell carcinoma patients.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Female; Humans; Male; Melatonin; | 2021 |
A novel melatonin-regulated lncRNA suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression.
Topics: Cell Line, Tumor; Cell Movement; DNA Methyltransferase 3A; Humans; Melatonin; Mouth Neoplasms; RNA, | 2021 |
Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
Topics: Acetylation; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle | 2017 |
Melatonin Inhibits Reactive Oxygen Species-Driven Proliferation, Epithelial-Mesenchymal Transition, and Vasculogenic Mimicry in Oral Cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Melatoni | 2018 |
Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; | 2014 |
Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation.
Topics: Acetylation; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Movement; Enzyme Activation | 2016 |